뇌염 치료 시장 기회, 성장 촉진 요인, 산업 동향 분석, 예측(2025-2034년)

The Global Encephalitis Treatment Market was valued at USD 22.3 billion in 2024 and is projected to grow at a CAGR of 5.2% during 2025-2034. This market is poised for steady expansion as cases of encephalitis continue to rise worldwide, driven by a surge in viral infections and increasing exposure to disease-causing vectors due to environmental changes. As more individuals are diagnosed with this serious neurological condition, healthcare systems are under growing pressure to provide timely and effective treatment options. The rising prevalence of vector-borne diseases, combined with the growing elderly population more susceptible to encephalitis, is accelerating the demand for advanced therapeutic solutions.

Additionally, the introduction of next-generation antiviral agents, immunotherapies, and improved diagnostic technologies is further reshaping the landscape of encephalitis treatment. Healthcare providers and pharmaceutical companies are working together to innovate treatment pathways that not only address acute inflammation but also prevent long-term neurological damage. The growing emphasis on early diagnosis and intervention, especially in developed economies, is creating a favorable environment for market expansion. Alongside this, increased public awareness and government-led health initiatives are pushing the demand for better treatment accessibility across developing nations, making encephalitis treatment a key focus area in global healthcare.

The market is segmented into two primary categories based on disease type: primary encephalitis and secondary encephalitis. Primary encephalitis, directly caused by viral infections leading to brain inflammation, dominated the global market in 2024 with a 69.8% share. As incidences of viral infections climb, especially those transmitted by mosquitoes and ticks, primary encephalitis cases are growing, creating significant demand for effective treatment solutions. The availability of antiviral drugs is essential in managing these cases, as they help reduce inflammation and mitigate neurological complications. Moreover, climate change continues to influence the spread of vector-borne diseases, directly impacting the prevalence of primary encephalitis and subsequently driving up the need for therapeutic interventions.

Based on treatment type, the encephalitis treatment market includes antibiotics, steroid injections, immunoglobulin therapy, plasmapheresis, antiviral agents, and other therapies. Among these, antiviral agents generated USD 6.3 billion in 2024, emerging as a dominant segment. The strong demand for antiviral medications is primarily fueled by the rising number of viral encephalitis cases worldwide. These drugs have become a critical part of standard treatment regimens due to their proven efficacy in managing inflammation and preventing serious brain damage. Increasing research and development efforts toward novel antiviral compounds, along with supportive government initiatives and enhanced diagnostic tools, are expected to strengthen this segment's growth trajectory over the next decade.

The United States Encephalitis Treatment Market accounted for a substantial 92.6% share in 2024, generating USD 8 billion, and is forecasted to reach USD 12.9 billion by 2034. Growth in the U.S. is driven by heightened disease awareness, rapid diagnostic advancements, and widespread availability of innovative treatments. The country's robust healthcare infrastructure, coupled with significant healthcare spending, ensures that patients have access to cutting-edge therapies, reinforcing the nation's position as a leader in the encephalitis treatment space.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of encephalitis
    • 3.2.1.2 Growing awareness about encephalitis treatment
    • 3.2.1.3 Increased investment in research and development by pharmaceutical companies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost associated with treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Primary encephalitis
• 5.3 Secondary encephalitis

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Antiviral agents
• 6.3 Steroid injections
• 6.4 Antibiotics
• 6.5 Immunoglobulin therapy
• 6.6 Plasmapheresis
• 6.7 Other treatments

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral
• 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Specialty clinics
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Allergan
• 10.3 Basilea Pharmaceutica
• 10.4 F. Hoffmann-La Roche
• 10.5 GlaxoSmithKline
• 10.6 Melinta Therapeutics
• 10.7 Merck
• 10.8 Pfizer
• 10.9 Sanofi
• 10.10 Teva Pharmaceutical Industries